In the treatment of CXCL12/SDF-1α-secreting glioblastoma cells, anti-EGFRvIII CAR NK cells were used with overexpression of CXCR4 and the results showed an increase in chemotaxis towards these tumor cells, complete tumor remission in a number of mice, and an increased overall survival [110]. This evidence concerns the gene CXCL12 and glioblastoma.